This post was written by Erin A. Janssen.

On February 6, 2012, the FDA adopted as a final rule, without change, the interim final rule from December 28, 2007 that permitted FDA Center Directors to grant exceptions or alternatives to certain regulatory labeling requirements applicable to human drugs, biological products, or medical devices that are or will be included in the Strategic National Stockpile. FDA took action via the announcement in the Federal Register to complete the rulemaking initiated with the interim final rule.